Body

The FDA has authorized the emergency use of Evusheld for use as pre-exposure prophylaxis of COVID-19 in certain adults and pediatric patients who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and meet either condition below:

  • Those with moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medication or treatments and may not mount an adequate immune response to COVID-19 vaccination, or
  • For whom vaccination with any available COVID-19 vaccine in not recommended due to a history of severe adverse reaction to a COVID-19 vaccines(s) and/or COVID-19 vaccine(S) component(s).

REMEMBER: Evusheld is not authorized for use as a treatment of COVID-19 or as post-exposure prophylaxis of COVID-19. Evusheld cannot be administered for at least two weeks after receiving a COVID-19 vaccination or booster.

Download Evusheld Fact Sheet

Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include but are not limited to:

  • Active treatment for solid tumor and hematologic malignancies
  • Receipt of solid-organ transplant and taking immunosuppressive therapy
  • Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
  • Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
  • Advanced or untreated HIV infection (people with HIV and CD4 cell counts

Prioritization Tiers:

  • Received B-cell depleting therapies (e.g. rituximab, Obinutuzumab, ocrelizumab, alemtuzumab) within the last 6 month and is over the age of 66
  • Received B-cell depleting therapies, within the last 6 months, and is under the age of 65. Any ongoing use of BTK inhibitors (ibrutinib, acalabrutinib)
  • Received allogenic HCT or CAR-T therapy within the past 6-12 months
  • Lung transplants, other SOT recipients on continual belatacept therapy, or multiple myeloma (actively receiving treatment)
  • Autologous HCT, or other solid organ transplants over the age of 65 and withing 6 months of transplant
  • Other actively treated hematologic malignancies or severe congenital immunodeficiency syndromes; patients receiving high-dose cyclophosphamide or similarly immunosuppressive regimens
  • Solid tumor malignancies or inflammatory syndromes on immunomodulatory chemotherapy (e.g: high-dose cyclophosphamide); advanced AIDS

LIMITATIONS OF AUTHORIZED USE:

  • EVUSHELD is not authorized for use in individuals:
    • For treatment of COVID-19, or
    • For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2.
  • Pre-exposure prophylaxis with EVUSHELD is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended.
    • Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate to severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID-19 vaccination.
  • In individuals who have received a COVID-19 vaccine, EVUSHELD should be administered at least two weeks after vaccination.

Additional Information:

  • St. Charles has a limited supply of Evusheld
  • Prioritization is given to high-risk patients
  • The Cancer Infusion Center (Bend location) is the only site offering Evusheld
  • Injections are available Monday – Friday
  • Evusheld requires 60 min observation time following administration
  • All patients must abide by current Covid Screening and Visitor policies

Ordering Evusheld

  • Providers can order this treatment for their patients through Epic or using the online form button below.
  • To order in Epic search LAAB Injection in the preference list or database.
  • Once the referral is reviewed by the pharmacy team, the patient will be contacted to schedule.

Evusheld Treatment Order Form